PharmTech Drug Digest 11.20
News|Articles|June 24, 2015

Juniper and OxSonics Form Cancer Drug Delivery Pact

Juniper Pharma Services has entered into a long-term collaboration with OxSonics to support the development, scale-up, and GMP manufacturing of OxSonics’ proprietary sono-sensitive particles.

Juniper Pharma Services, formerly known as Molecular Profiles, has entered into a long-term collaboration with OxSonics to support the development, scale-up, and GMP manufacturing of OxSonics’ proprietary sono-sensitive particles. These injectable particles, which when used in conjunction with new generation ultrasound devices, can be applied to a range of therapeutic applications including an oncological drug delivery platform called SonoTran. SonoTran is designed to enhance the delivery of anti-cancer drugs deep into and throughout solid tumors.

Colin Story, CEO of OxSonics, said in a press release that this technology has potential to deliver a step-change in the performance of drugs for solid tumors. The company is working with Juniper Pharma Services to take the development of its proprietary sono-sensitive particles from a laboratory-scale to clinical trial-scale and grade.

According to Story, OxSonics’ main objective is to commercialize the SonoTran platform, which has the capability to overcome one of the challenges facing solid tumor cancer therapy by delivering drugs throughout tumor volumes including to those areas that lie farthest from blood vessels. Under this agreement, Juniper Pharma Services will manufacture the technology for clinical studies on behalf of OxSonics

Source: Juniper Pharmaceuticals 

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.